under Exhibitor Profiles I don't see Exel? It shows the following companies: Abbvie,AstraZeneca,Boehringer Ingelheim,Bristol-Myers Squibb,Clovis Oncology,Helsinn Group,Lilly Oncology,MSD,Novartis Oncology,Otsuka Pharmaceutical Europe,Pfizer Oncology,and Roche.
Geneva, Switzerland, 17 April 2015 -- A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland.
Dr. Oliver Gautschi, a medical oncologist from Lucern Cantonal Hospital in Switzerland, presented the results of the retrospective EURAF cohort study, which included lung cancer patients whose tumours carried specific mutations in the BRAF gene. The study was conducted by a network of European oncologists, without company involvement.
BRAF mutations are commonly seen in melanoma patients, and are found in about 2% of lung adenocarcinomas, Gautschi explains. Several inhibitors of the B-Raf protein, including vemurafenib and dabrafenib, have been developed for use in melanoma patients, however there is currently no approved drug for BRAF-mutant lung cancer.
As a result, experience with B-Raf inhibitors in lung cancer remains limited. "In the current study, we wanted to find out how many patients in Europe received B-Raf inhibitors outside of a clinical trial, and what their outcomes were," Gautschi says.
The EURAF study gathered information on 35 lung cancer patients who had been identified as carrying BRAF mutations, who were treated with B-Raf inhibitors between 2012 and 2014.
Most of those patients received vemurafenib, some dabrafenib, and one sorafenib. Overall response rate was 53% as measured by the widely used Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. Overall, progression-free survival time in this group was 5 months.
Most patients were pretreated, and not eligible for enrolment in a clinical trial, which means these results are encouraging, the researchers say, although the study's small size and retrospective nature mean the analysis of the magnitude of benefit should be treated cautiously.
"The bottom line is that clinicians should be sure to test patients for so-called 'rare' driver mutations in lung cancer, because individual patients may derive substantial benefit from targeted therapy," says Gautschi.
Commenting on the findings, Dr David Planchard, pulmonary oncologist at Gustave Roussy in Villejuif, France, said that the results of the trial confirm the benefit of B-Raf inhibitors in BRAF-mutant non-small cell lung cancer. The current trial also confirmed the good tolerance of the drugs with no new side-effects, he said. Planchard and colleagues have presented a separate phase II study in this area with dabrafenib .
"This trial is important because due to the low frequency of this mutation in non-small cell lung cancer we will have few trials on this population," Planchard commented. "The more data we have, the better we understand how important it is to test for the mutation, especially in adenocarcinomas, and to expose mutation-positive patients to a specific B-Raf inhibitor."
The results also add to growing support for the approval of B-Raf inhibitors for use in lung cancer, Planchard added. This is important because the rarity of this mutation means that performing the kind of randomized phase III trials usually required for licensing approval will be extremely difficult, he noted.
Looking ahead, it will also be important to see results of combination therapy with inhibitors of B-Raf and a related protein, Mek, in non-small cell lung cancer carrying BRAF-V600E mutations, the researchers note, as this combination has shown a higher clinical benefit in BRAF-mutant melanoma.
Nitwit. With your help we sure can't go wrong? Say isn't that the only tool Warren Buffet ever uses?
Back in 2008 or 2009, I believe you used the handle nomad_celcius12. You posted incessantly venomous comment after comment. Nothing but your personal opinions without merit .You just wasted your time.Then you stopped after about 5 years.Now your back as nomad_1957;posting the same kind of worthless nonsense.
From Street article: With the designation, cabozantinib is now also eligible for a Priority Review of a New Drug Application.Nothing but good news today.That's why the price rose today.There is no getting around that fact.
Wrong it is not a,"pretty much a gimmie;look, snowflakeformationxy said, "My source is a FDA site - FDA Voice - Fast.In 2014, 19 or 46% of 41 drugs were approved as being designated as - fast track."
I like this part:"Once a drug receives Fast Track designation, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients."
oops a few mistypes. correction is: If there is no indication it will it wouldn't be given fast.The FDA doesn't williy-nilliy give that satus.It's a positive to get fast track.Plain and simple.It's not given without some merit too the drug.If there no indications that it will work it would be given.
oncodoc02138 "s great post "Fasttrack, and what it means,"says it clear and simple.
The FDA doesn't williy-nilliy give that satus.It's a positive to get fast track.Plain and simple.It's not given without some merit too the drug.If there no indications that it will work it would be given.
Check out customized semanresu's 1993 Ford Mustang photos, parts, specs, modification, for sale information and follow semanresu in Glendale AZ for any latest updates ...
Have you read the article?Or seen the 60 minute piece?That's where you should start.
Pelley talked to molecular biologist Matthias Gromeier, who came up with the idea of using polio against tumors.
Dr. Henry Friedman, a neuro-oncologist who is the deputy director of the Brain Tumor Center at Duke University, talks about how his views of the polio therapy have changed over time.Dr. Henry Friedman said it works on any type of Cancer.
"I thought he [Gromeier] was nuts," Friedman says. "I really thought he was using a weapon that produced paralysis."
But that view 15 years ago has given way to optimism. "This, to me, is the most promising therapy I have seen in my career, period," Friedman tells Pelley.
Gromeier came up with a genetically modified polio virus that removes a protective shield from cancers, allowing the immune system to fight back.
Cancer can no longer be seen in two patients who received the polio treatment three years ago. One patient, retired cardiologist Dr. Fritz Andersen, says, "I feel it's a cure and I live my life that way."
It will be on 60 Minutes Sunday
You are not able to tell what will happen.You can only guess.Every financial program on T.V and every publication concering money will have the thoughts of many people; and none of them agree 100% about any reason for market swings or the change in any stock price.They use all kinds of theories devised by supposed experts; but in most cased they just find ways too supprot their own intersets.Ther is no exact science to playing the markets and stocks.Small and early stage BioTech stocks are very speculative and could fail or the stock become a huge winner.It all depends on the sci. and you and no one else knows if Exel trials will succed until results are inWe all have to wiat for the Cobi and on going Cabo results.Soon we'll have qtly. results and in the next quarter trial rewsults.Till then you can spew on and on but it is only your own ranting that you hear.
Since you spend all you time posting here my impression is you are incapacitated and unable to do much else. You have a sallow life and that is so sad.